Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative ...

The United States Huntington's Disease Treatment Market is set to expand significantly, with an expected CAGR of 15.22% from ...

However, in late September 2025, scientists successfully treated Huntington’s for the first time in a ground-breaking study.

Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval, BioSpace looks at ...

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo, in ...

Analysts are estimating that Neurocrine Biosciences will report an earnings per share (EPS) of $1.87. Neurocrine Biosciences ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Good day, everyone, and welcome to today's Neurocrine Biosciences Third Quarter 2025 Results Call.

Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea associated with Huntington’s disease. Rounding ...